Top

Published in:

Open Access 01-12-2016 | Research

Gene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure

Authors: Alette Ortega-Gómez, Claudia Rangel-Escareño, Camilo Molina-Romero, Eleazar Omar Macedo-Pérez, Alejandro Avilés-Salas, Alejandra Lara-García, Gerardo Alanis-Funes, Rubén Rodríguez-Bautista, Alfredo Hidalgo-Miranda, Oscar Arrieta

Published in: Respiratory Research | Issue 1/2016

Abstract

Background

Tobacco-smoke is the major etiological factor related to lung cancer. However, other important factor is chronic wood smoke exposure (WSE). Approximately 30 % of lung cancer patients in Mexico have a history of WSE, and present different clinical, pathological and molecular characteristics compared to tobacco related lung cancer, including differences in mutational profiles. There are several molecular alterations identified in WSE associated lung cancer, however most studies have focused on the analysis of changes in several pathogenesis related proteins.

Methods

Our group evaluated gene expression profiles of primary lung adenocarcinoma, from patients with history of WSE or tobacco exposure. Differential expression between these two groups were studied through gene expression microarrays.

Results

Results of the gene expression profiling revealed 57 statistically significant genes (p < 0.01). The associated biological functional pathways included: lipid metabolism, biochemistry of small molecules, molecular transport, cell morphology, function and maintenance. A highlight of our analysis is that three of the main functional networks represent 37 differentially expressed genes out of the 57 found. These hubs are related with ubiquitin C, GABA(A) receptor-associated like protein; and the PI3K/AKT and MEK/ERK signaling pathways.

Conclusion

Our results reflect the intrinsic biology that sustains the development of adenocarcinoma related to WSE and show that there is a different gene expression profile of WSE associated lung adenocarcinoma compared to tobacco exposure, suggesting that they arise through different carcinogenic mechanisms, which may explain the clinical and mutation profile divergences between both lung adenocarcinomas.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. doi:10.1002/ijc.29210.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254.CrossRefPubMed

Yu YH, Liao CC, Hsu WH, Chen HJ, Liao WC, Muo CH, et al. Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J Thorac Oncol. 2011;6(1):32–7. doi:10.1097/JTO.0b013e3181fb4fcc.CrossRefPubMed

IARC. Lung Cancer Estimated Incidence, Mortality and Prevalence. In: Cancer Fact Sheet. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. 2012. Accessed November 21 2015.

Arrieta O, Guzman-de Alba E, Alba-Lopez LF, Acosta-Espinoza A, Alatorre-Alexander J, Alexander-Meza JF, et al. National consensus of diagnosis and treatment of non-small cell lung cancer. Rev Invest Clin. 2013;65 Suppl 1:S5–84.PubMed

Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers--a different disease. Nat Rev Cancer. 2007;7(10):778–90. doi:10.1038/nrc2190.CrossRefPubMed

Cufari ME, Proli C, Phull M, Raubenheimer H, Al Sahaf M, Asadi N, et al., editors. Increasing Incidence of Non-Smoking Lung Cancer: Presentation of Patients with Early Disease to a Tertiary Institution in the UK. 16TH WORLD CONFERENCE ON LUNG CANCER; 2015 September 6–9; Denver, CO: International Association of the Study of Lung Cancer (IASLC).

Pelosof L, Ahn C, Horn L, Madrigales A, Cox J, Roberts JN, et al., editors. Increasing Incidence of Never Smokers in Non Small Cell Lung Cancer (NSCLC) Patients. 16TH WORLD CONFERENCE ON LUNG CANCER; 2015 September 6–9; Denver, CO: International Association of the Study of Lung Cancer (IASLC).

Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e1S–29S. doi:10.1378/chest.12-2345.CrossRefPubMedPubMedCentral

10.

Pua BB, Dou E, O'Connor K, Crawford CB. Integrating smoking cessation into lung cancer screening programs. Clin Imaging. 2015. doi:10.1016/j.clinimag.2015.05.004.PubMed

11.

Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374(9691):733–43. doi:10.1016/S0140-6736(09)61303-9.CrossRefPubMed

12.

Naeher LP, Brauer M, Lipsett M, Zelikoff JT, Simpson CD, Koenig JQ, et al. Woodsmoke health effects: a review. Inhal Toxicol. 2007;19(1):67–106. doi:10.1080/08958370600985875.CrossRefPubMed

13.

Hernandez-Garduno E, Brauer M, Perez-Neria J, Vedal S. Wood smoke exposure and lung adenocarcinoma in non-smoking Mexican women. Int J Tuberc Lung Dis. 2004;8(3):377–83.PubMed

14.

Zelikoff JT, Chen LC, Cohen MD, Schlesinger RB. The toxicology of inhaled woodsmoke. J Toxicol Environ Health B Crit Rev. 2002;5(3):269–82. doi:10.1080/10937400290070062.CrossRefPubMed

15.

Arrieta O, Campos-Parra AD, Zuloaga C, Aviles A, Sanchez-Reyes R, Manriquez ME, et al. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. J Thorac Oncol. 2012;7(8):1228–34. doi:10.1097/JTO.0b013e3182582a93.CrossRefPubMed

16.

Delgado J, Martinez LM, Sanchez TT, Ramirez A, Iturria C, Gonzalez-Avila G. Lung cancer pathogenesis associated with wood smoke exposure. Chest. 2005;128(1):124–31. doi:10.1378/chest.128.1.124.CrossRefPubMed

17.

Montano M, Beccerril C, Ruiz V, Ramos C, Sansores RH, Gonzalez-Avila G. Matrix metalloproteinases activity in COPD associated with wood smoke. Chest. 2004;125(2):466–72.CrossRefPubMed

18.

Arrieta O, Cardona AF, Martin C, Mas-Lopez L, Corrales-Rodriguez L, Bramuglia G, et al. Updated frequency of EGFR and KRAS mutations in nonsmall-cell lung cancer in Latin America: the Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). J Thorac Oncol. 2015;10(5):838–43. doi:10.1097/JTO.0000000000000481.CrossRefPubMed

19.

Arrieta O, Ramirez-Tirado LA, Baez-Saldana R, Pena-Curiel O, Soca-Chafre G, Macedo-Perez EO. Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox". Lung Cancer. 2015;90(2):161–6. doi:10.1016/j.lungcan.2015.08.010.CrossRefPubMed

20.

Luo YH, Wu CH, Wu WS, Huang CY, Su WJ, Tsai CM, et al. Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs. J Thorac Oncol. 2012;7(2):299–305. doi:10.1097/JTO.0b013e31823c588d.CrossRefPubMed

21.

Arrieta O, Martinez-Barrera L, Trevino S, Guzman E, Castillo-Gonzalez P, Rios-Trejo MA, et al. Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study. J Thorac Oncol. 2008;3(8):887–93. doi:10.1097/JTO.0b013e31818026f6.CrossRefPubMed

22.

Behera D, Jindal SK. Respiratory symptoms in Indian women using domestic cooking fuels. Chest. 1991;100(2):385–8.CrossRefPubMed

23.

Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249–64. doi:10.1093/biostatistics/4.2.249.CrossRefPubMed

24.

Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19(2):185–93.CrossRefPubMed

25.

Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. Bioinformatics. 2010;26(19):2363–7. doi:10.1093/bioinformatics/btq431.CrossRefPubMedPubMedCentral

26.

Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28(6):882–3. doi:10.1093/bioinformatics/bts034.CrossRefPubMedPubMedCentral

27.

Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3. doi:10.2202/1544-6115.1027.PubMed

28.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. doi:10.1002/ijc.25516.CrossRefPubMed

29.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.CrossRefPubMed

30.

Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80. doi:10.1056/NEJMra0802714.CrossRefPubMed

31.

Lee YJ, Kim JH, Kim SK, Ha SJ, Mok TS, Mitsudomi T, et al. Lung cancer in never smokers: change of a mindset in the molecular era. Lung Cancer. 2011;72(1):9–15. doi:10.1016/j.lungcan.2010.12.013.CrossRefPubMed

32.

Word B, Lyn-Cook Jr LE, Mwamba B, Wang H, Lyn-Cook B, Hammons G. Cigarette smoke condensate induces differential expression and promoter methylation profiles of critical genes involved in lung cancer in NL-20 lung cells in vitro: short-term and chronic exposure. Int J Toxicol. 2013;32(1):23–31. doi:10.1177/1091581812465902.CrossRefPubMed

33.

Lowe FJ, Luettich K, Gregg EO. Lung cancer biomarkers for the assessment of modified risk tobacco products: an oxidative stress perspective. Biomarkers. 2013;18(3):183–95. doi:10.3109/1354750X.2013.777116.CrossRefPubMedPubMedCentral

34.

Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer. 2006;6(10):776–88. doi:10.1038/nrc1994.CrossRefPubMed

35.

Tang Y, Geng Y, Luo J, Shen W, Zhu W, Meng C, et al. Downregulation of ubiquitin inhibits the proliferation and radioresistance of non-small cell lung cancer cells in vitro and in vivo. Sci Rep. 2015;5:9476. doi:10.1038/srep09476.CrossRefPubMedPubMedCentral

36.

Berthier A, Seguin S, Sasco AJ, Bobin JY, De Laroche G, Datchary J, et al. High expression of gabarapl1 is associated with a better outcome for patients with lymph node-positive breast cancer. Br J Cancer. 2010;102(6):1024–31. doi:10.1038/sj.bjc.6605568.CrossRefPubMedPubMedCentral

37.

Roberts SS, Mori M, Pattee P, Lapidus J, Mathews R, O'Malley JP, et al. GABAergic system gene expression predicts clinical outcome in patients with neuroblastoma. J Clin Oncol. 2004;22(20):4127–34. doi:10.1200/JCO.2004.02.032.CrossRefPubMed

38.

Klebig C, Seitz S, Arnold W, Deutschmann N, Pacyna-Gengelbach M, Scherneck S, et al. Characterization of {gamma}-aminobutyric acid type A receptor-associated protein, a novel tumor suppressor, showing reduced expression in breast cancer. Cancer Res. 2005;65(2):394–400.PubMed

39.

Nemos C, Mansuy V, Vernier-Magnin S, Fraichard A, Jouvenot M, Delage-Mourroux R. Expression of gec1/GABARAPL1 versus GABARAP mRNAs in human: predominance of gec1/GABARAPL1 in the central nervous system. Brain Res Mol Brain Res. 2003;119(2):216–9.CrossRefPubMed

40.

Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, et al. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Adv Med Sci. 2011;56(2):275–84. doi:10.2478/v10039-011-0043-x.CrossRefPubMed

41.

Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res. 2003;9(6):2316–26.PubMed

42.

Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 2007;4(10):1681–89. doi:10.1371/journal.pmed.0040316. discussion 90.CrossRefPubMed

43.

Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, et al. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res. 2007;67(24):11867–75. doi:10.1158/0008-5472.CAN-07-1961.CrossRefPubMed

44.

Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev. 2008;18(1):73–9. doi:10.1016/j.gde.2008.01.004.CrossRefPubMed

45.

Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 2007;4(10):e294. doi:10.1371/journal.pmed.0040294.CrossRefPubMedPubMedCentral

46.

Sood A, Petersen H, Blanchette CM, Meek P, Picchi MA, Belinsky SA, et al. Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers. Am J Respir Crit Care Med. 2010;182(9):1098–104. doi:10.1164/rccm.201002-0222OC.CrossRefPubMedPubMedCentral

47.

Danielsen PH, Moller P, Jensen KA, Sharma AK, Wallin H, Bossi R, et al. Oxidative stress, DNA damage, and inflammation induced by ambient air and wood smoke particulate matter in human A549 and THP-1 cell lines. Chem Res Toxicol. 2011;24(2):168–84. doi:10.1021/tx100407m.CrossRefPubMed

48.

Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21(14):2787–99. doi:10.1200/JCO.2003.01.504.CrossRefPubMed

49.

Janmaat ML, Giaccone G. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today. 2003;39 Suppl C:61–80.PubMed

50.

Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002;94(5):1593–611.CrossRefPubMed

51.

Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 2003;4(7):397–406.CrossRefPubMed

52.

Campos-Parra AD, Zuloaga C, Manriquez ME, Aviles A, Borbolla-Escoboza J, Cardona A, et al. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. Am J Clin Oncol. 2015;38(1):33–40. doi:10.1097/COC.0b013e318287bb23.CrossRefPubMed

53.

Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–32. doi:10.1056/NEJMoa050753.CrossRefPubMed

54.

Arrieta O, Cardona AF, Federico Bramuglia G, Gallo A, Campos-Parra AD, Serrano S, et al. Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol. 2011;6(11):1955–9. doi:10.1097/JTO.0b013e31822f655f.CrossRefPubMed

55.

Arrieta O, Cardona AF, Corrales L, Campos-Parra AD, Sanchez-Reyes R, Amieva-Rivera E, et al. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung Cancer. 2015;87(2):169–75. doi:10.1016/j.lungcan.2014.12.009.CrossRefPubMed

56.

Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9(7):517–31. doi:10.1038/nrm2438.CrossRefPubMedPubMedCentral

57.

Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. J Clin Oncol. 2013;31(8):1089–96. doi:10.1200/JCO.2012.43.9422.CrossRefPubMedPubMedCentral

58.

Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–90. doi:10.1038/sj.onc.1210421.CrossRefPubMed

59.

Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, Van Waes C. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets. 2011;15(1):63–74. doi:10.1517/14728222.2011.541440.CrossRefPubMedPubMedCentral

60.

Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550–62. doi:10.1038/nrc2664.CrossRefPubMed

61.

Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329–41. doi:10.1038/nrm2882.CrossRefPubMed

62.

Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501. doi:10.1038/nrc839.CrossRefPubMed

63.

Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 2008;68(17):6913–21. doi:10.1158/0008-5472.CAN-07-5084.CrossRefPubMedPubMedCentral

64.

Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, De Gisi S, et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle. 2008;7(5):665–9.CrossRefPubMed

65.

Joshi M, Rizvi SM, Belani CP. Afatinib for the treatment of metastatic non-small cell lung cancer. Cancer Manage Res. 2015;7:75–82. doi:10.2147/CMAR.S51808.CrossRef

66.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 2004;64(15):5355–62. doi:10.1158/0008-5472.CAN-04-0562.CrossRefPubMed

Title: Gene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure
Authors: Alette Ortega-Gómez
Claudia Rangel-Escareño
Camilo Molina-Romero
Eleazar Omar Macedo-Pérez
Alejandro Avilés-Salas
Alejandra Lara-García
Gerardo Alanis-Funes
Rubén Rodríguez-Bautista
Alfredo Hidalgo-Miranda
Oscar Arrieta
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Respiratory Research / Issue 1/2016
Electronic ISSN: 1465-993X
DOI: https://doi.org/10.1186/s12931-016-0346-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Gene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2016

Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells

Electronic cigarettes: a survey of perceived patient use and attitudes among members of the British thoracic oncology group

Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients

Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung

Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial

Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page